Abstract: Physically and chemically stable oral liquid formulations of Givinostat (Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride) are disclosed, together with methods for the preparation thereof. Such oral formulations are in the form of aqueous suspensions and contain Givinostat and/or pharmaceutically acceptable salts and/or derivatives thereof, at least a wetting agent and/or at least a density-imparting agent. Such formulations are suitable for oral administration for systemic therapeutic action.
Type:
Grant
Filed:
October 28, 2016
Date of Patent:
June 23, 2020
Assignee:
ITALFARMACO SPA
Inventors:
Giuseppe Colombo, Roberta Artico, Paolo Mascagni, Maria Valmen Monzani, Silvia Puccianti
Abstract: A gel for topical application for alleviating food cravings is disclosed, which includes the steps of: periodically applying a gel topically to a user's skin, wherein said gel comprises: about 45.0 percent by weight of deionized water; about 10.0 percent by weight of benzyl alcohol; about 40.0 percent by weight of ethyl alcohol; about 0.2 percent by weight of tocopherol acetate; about 0.15 percent by weight of docosahexaenoic acid (DHA); about 1.15 percent by weight of resveratrol; about 1.0 percent by weight of a cross-linked polyacrylic acid copolymer; about 0.1 percent by weight of ethylenediaminetetraacetic acid (EDTA); about 200 ?L of lemon essential oil; and, from about 100 ?L to 200 ?L of triethanolamine.
Abstract: Disclosed are compositions comprising inorganic UV-absorbing agents and the use of such compositions, in particular for protecting a subject or the surface of an inanimate object against a harmful effect of ultraviolet radiation.
Type:
Grant
Filed:
September 25, 2017
Date of Patent:
June 9, 2020
Assignee:
LANDA LABS (2012) LTD.
Inventors:
Benzion Landa, Sagi Abramovich, Snir Dor
Abstract: The disclosure provides drug delivery devices and methods of making and using the drug delivery devices. The devices include single and multi-layer polymer films made by a breath figure technique having therapeutic agents associated therewith. For example, the devices may be a dual layer polymer film wherein the first layer includes a therapeutic agent incorporated into it by spin coating the first agent with a polymer solution and the second agent is incorporated into the second layer by loading the agent into pores of the second layer after it is spin coated onto the first layer. In some cases one layer provides a burst release and the second layer provides a slow release drug delivery profile. The devices may take on the form of a surgical mesh with a slow release therapeutic drug.
Type:
Grant
Filed:
August 11, 2018
Date of Patent:
May 19, 2020
Assignee:
THE ADMINSTRATORS OF THE TULANE EDUCATIONAL FUND
Inventors:
Diane A. Blake, Vijay T. John, Ramesh Ayyala, Thiruselvam Ponnusamy
Abstract: The invention relates to a cosmetic treatment process, in particular for caring for or making up keratin materials, comprising the following steps: a) a step of applying, to the keratin materials, a cosmetic composition comprising a compound comprising at least 2 maleimide groups; b) a step of applying a cosmetic composition comprising a compound comprising at least 2 furfuryl groups. The invention also relates to a kit comprising the two compositions, enabling said process to be carried out. The invention also relates to copolymers furfuryl (meth)acrylate, specifically (meth)acrylamide, and addition monomer chosen from polyethylene glycol (meth)acrylates and polydimethylsiloxanes with mono(meth)acryloyloxy end group.
Type:
Grant
Filed:
November 28, 2016
Date of Patent:
May 12, 2020
Assignee:
L'OREAL
Inventors:
Gwenaëlle Jegou, Philippe Barbarat, Gérard Malle
Abstract: The present disclosure relates to aqueous oral solutions comprising baclofen. In one embodiment, the aqueous oral solutions comprise a buffer comprising citric acid, a salt of citric acid, or any combination thereof, and are stored at from about 2° C. to about 8° C. The present disclosure also relates to buffer free aqueous oral solutions comprising baclofen. Additionally, the present disclosure relates to an assay for determining the amount of an impurity, 4-(3-carboxymethyl)-3-hydroxy-2,5-dioxopyrrolidin-1-yl)-3-(4-chlorophenyl)butanoic acid, in a baclofen containing solution, and to methods of treatment using such aqueous oral solutions.
Abstract: The present disclosure relates to cosmetic compositions that provide immediate skin-tightening and long-lasting improvements to the skin for the treatment of, for example, eye bags, facial wrinkles, and other age-related skin imperfections. The compositions comprise: (a) a first film former sodium silicate; (b) a second film former; (c) at least one polyvalent silicate; (d) at least one anionic associative polymeric thickener; (e) a third film former VP/VA Copolymer; (f) at least two plasticizer; (g) at least one treated or non treated iron oxide pigments; and (h) optionally at least one cosmetic powder.
Type:
Grant
Filed:
October 10, 2017
Date of Patent:
March 17, 2020
Assignee:
L'OREAL
Inventors:
Mariana Montoya, Angelike A. Galdi, Susan Halpern Chirch, Hubert Tunchiao Lam
Abstract: A beauty care product is provided. The beauty care product has a multi-layered barrier patch with a non-foamed first layer and a foamed second layer. The non-foamed first layer has a non-foamed polymer film with a first surface and a thickness from 5 microns to 250 microns. The foamed second layer has a foamed polymer film comprising a Mean Void Volume Percentage from 45% to 80% and a thickness of from 10 microns to 250 microns. The beauty care product also has a cosmetic composition with an effective amount of a skin active agent and a pressure sensitive adhesive.
Type:
Grant
Filed:
October 18, 2016
Date of Patent:
March 3, 2020
Assignee:
The Procter & Gamble Company
Inventors:
Emily Charlotte Boswell, Elizabeth Anne Wilder, Michael Remus
Abstract: Brain-penetrating polymeric nanoparticles that can be loaded with drugs and are optimized for intracranial convection-enhanced delivery (CED) have been developed. In the preferred embodiment, these are loaded with FDA-approved compounds, identified through library screening to target brain cancer stem cells (BSCSs). The particles are formed by emulsifying a polymer-drug solution, then removing solvent and centrifuging at a first force to remove the larger particles, then collecting the smaller particles using a second higher force to sediment the smaller particles having a diameter of less than 100 nm, more preferably less than 90 nanometers average diameter, able to penetrate brain interstitial spaces.
Type:
Grant
Filed:
May 6, 2013
Date of Patent:
February 11, 2020
Assignee:
Yale University
Inventors:
Jiangbing Zhou, Toral R. Patel, Joseph M. Piepmeier, William Mark Saltzman
Abstract: Provided are a dermal adhesive composed of a radiation-curable resin and capable of reducing stuffiness that causes rash or itch, a patch including the dermal adhesive, and a method for producing the dermal adhesive. Also provided is a porous membranous dermal adhesive formed through irradiation of a radiation-curable resin with radiation rays. Further provided is a patch including a base sheet and the dermal adhesive disposed on the base sheet. Still further provided is a method for producing a porous membranous dermal adhesive, the method including applying a dermal adhesive composition containing a radiation-curable resin to an adherend so as to form a porous membranous dermal adhesive, and irradiating the dermal adhesive composition with radiation rays.
Abstract: Redox signaling gels are disclosed. Such gels include a composition with at least one reactive oxygen species (ROS) and a rheology modifier. Also presented herein is a process for making the gels which includes making the composition by taking the steps of purifying water to produce ultra-pure water, combining a salt to the ultra-pure water to create a salinated water, electrolyzing the salinated water at a temperature of 4.3 to 5.8° C. such that the electrolyzing is accomplished with an anode, cathode and power source such that the power source comprises a transformer and a rectifier and does not comprise a filter capacitor.
Abstract: Personal care compositions that include bioactive ingredients derived from achachairu and methods of making the same. The bioactive compositions (ingredients) of the present invention may be free of or substantially free of benzophenones and/or protein, and may exhibit anti-inflammatory, anti-oxidant, anti-aging, and/or anti-protein loss properties. The achachairu ingredient may be in the form of a serum fraction and/or an extract. The personal care compositions are formulated for topical use on skin and/or hair.
Type:
Grant
Filed:
December 5, 2016
Date of Patent:
January 21, 2020
Assignee:
The Procter & Gamble Company
Inventors:
Rosemarie Osborne, Lisa Ann Mullins, Michael Koganov
Abstract: The present invention relates to stable, liquid parenteral formulations of Melphalan or pharmaceutically acceptable salts thereof. Further this invention also describes process of preparing such formulations.
Type:
Grant
Filed:
June 29, 2016
Date of Patent:
January 21, 2020
Assignee:
LEIUTIS PHARMACEUTICALS PVT. LTD.
Inventors:
Kocherlakota Chandrashekhar, Banda Nagaraju
Abstract: A beauty care product is provided. The beauty care product has a multi-layered barrier patch with a non-foamed first layer and a foamed second layer. The non-foamed first layer has a non-foamed polymer film with a first surface and a thickness from 5 microns to 250 microns. The foamed second layer has a foamed polymer film comprising a Mean Void Volume Percentage from 45% to 80% and a thickness of from 10 microns to 250 microns. The beauty care product also has a cosmetic composition with an effective amount of a skin active agent and a pressure sensitive adhesive.
Type:
Grant
Filed:
October 18, 2016
Date of Patent:
January 21, 2020
Assignee:
The Procter & Gamble Company
Inventors:
Emily Charlotte Boswell, Elizabeth Anne Wilder, Michael Remus
Abstract: The present invention relates generally to mascara compositions that impart volume to the eyelashes while maintaining a smooth texture and high shine.
Abstract: An implantable drug eluting medical device includes a polymer substrate having a surface, a first plurality of nanofibers, and at least one antimicrobial drug. Each of the first plurality of nanofibers includes a first portion interpenetrated with the surface of the substrate to mechanically fix the nanofiber to the substrate, and a second portion projecting from the surface. The at least one antimicrobial drug is disposed within or among the second portion of the first plurality of nanofibers.
Type:
Grant
Filed:
December 15, 2017
Date of Patent:
December 31, 2019
Assignee:
Cardiac Pacemakers, Inc.
Inventors:
Mary M. Byron, David R. Wulfman, Angelo Fruci, Adam McGraw, Danielle Frankson, Gregory J. Sherwood, Joseph T. Delaney, Jr., Adeniyi O. Aremu
Abstract: A method to prepare a cream product includes separately preparing an exclusively aqueous phase and a mixed fatty/aqueous phase, and assembling and emulsify the exclusively aqueous phase and the mixed fatty/aqueous phase.
Abstract: Provided are skin care compositions that are useful as SPF and UV absorption boosters in formulations containing inorganic metal oxides. The compositions comprise (a) (a) copolymer particles; (b) voided latex particles; (c) inorganic metal oxide particles; and (d) one or more dermatologically acceptable carriers. Also provided are methods of protecting skin from UVA and UVB damage comprising topically administering such compositions to the skin, and methods of boosting the SPF or UV absorption of a sunscreen composition containing inorganic metal oxide particles comprising including such copolymer particles and voided latex particles in the composition.
Type:
Grant
Filed:
August 24, 2016
Date of Patent:
December 17, 2019
Assignee:
Rohm and Haas Company
Inventors:
Kinjalbahen Joshi, Fanwen Zeng, Beth Cooper
Abstract: The present invention provides a novel drug delivery system for the controlled release of therapeutically active substances at a predetermined, essentially constant release rate over a prolonged period of time. The delivery system comprises at least one core comprising said therapeutically active substance(s), at least one membrane encasing the core and an intermediary layer of a substantially inert material, wherein the intermediary layer is applied between the core and the membrane or between two membrane layers.